Outcome or subgroup title,No. of studies,No. of participants,Statistical method,Effect size,comparison_name,comparison_id,effect_size,lower_ci,upper_ci,outcome_id,subgroup_id,outcome_name,subgroup_name
1.1 Improvement in vertigo frequency Show forest plot,2,,"Risk Ratio (M‐H, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,1,,Improvement in vertigo frequency Show forest plot
1.1.1 6 to ≤ 12 months,2,60,"Risk Ratio (M‐H, Random, 95% CI)","1.00 [0.92, 1.10]",Intratympanic corticosteroids versus placebo/no treatment,1,1.0,0.92,1.1,1,1,,6 to ≤ 12 months
1.1.2 > 12 months,2,58,"Risk Ratio (M‐H, Random, 95% CI)","1.03 [0.87, 1.23]",Intratympanic corticosteroids versus placebo/no treatment,1,1.03,0.87,1.23,1,1,,> 12 months
1.2 Improvement in vertigo frequency: sensitivity analysis for complete/substantial improvement Show forest plot,3,,"Risk Ratio (M‐H, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,2,,Improvement in vertigo frequency: sensitivity analysis for complete/substantial improvement Show forest plot
1.2.1 3 to < 6 months,1,36,"Risk Ratio (M‐H, Random, 95% CI)","1.15 [0.81, 1.64]",Intratympanic corticosteroids versus placebo/no treatment,1,1.15,0.81,1.64,1,2,,3 to < 6 months
1.2.2 6 to ≤ 12 months,3,96,"Risk Ratio (M‐H, Random, 95% CI)","1.23 [1.01, 1.48]",Intratympanic corticosteroids versus placebo/no treatment,1,1.23,1.01,1.48,1,2,,6 to ≤ 12 months
1.2.3 > 12 months,2,58,"Risk Ratio (M‐H, Random, 95% CI)","1.30 [1.02, 1.65]",Intratympanic corticosteroids versus placebo/no treatment,1,1.3,1.02,1.65,1,2,,> 12 months
1.3 Change in vertigo (global score) at 3 to < 6 months Show forest plot,1,44,"Mean Difference (IV, Random, 95% CI)","‐0.13 [‐0.42, 0.16]",Intratympanic corticosteroids versus placebo/no treatment,1,-0.13,-0.42,0.16,1,3,,Change in vertigo (global score) at 3 to < 6 months Show forest plot
1.4 Change in vertigo frequency at 3 to < 6 months Show forest plot,3,,"Mean Difference (IV, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,4,,Change in vertigo frequency at 3 to < 6 months Show forest plot
1.4.1 3 to < 6 months,3,,"Mean Difference (IV, Random, 95% CI)","‐0.05 [‐0.07, ‐0.02]",Intratympanic corticosteroids versus placebo/no treatment,1,-0.05,-0.07,-0.02,1,4,,3 to < 6 months
1.5 Change in vertigo frequency at 6 to < 12 months and > 12 months Show forest plot,1,,"Mean Difference (IV, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,5,,Change in vertigo frequency at 6 to < 12 months and > 12 months Show forest plot
1.5.1 6 to ≤ 12 months,1,20,"Mean Difference (IV, Random, 95% CI)","‐0.10 [‐0.79, 0.59]",Intratympanic corticosteroids versus placebo/no treatment,1,-0.1,-0.79,0.59,1,5,,6 to ≤ 12 months
1.5.2 > 12 months,1,18,"Mean Difference (IV, Random, 95% CI)","‐0.07 [‐0.84, 0.70]",Intratympanic corticosteroids versus placebo/no treatment,1,-0.07,-0.84,0.7,1,5,,> 12 months
1.6 Serious adverse events Show forest plot,4,500,"Risk Ratio (M‐H, Random, 95% CI)","0.64 [0.22, 1.85]",Intratympanic corticosteroids versus placebo/no treatment,1,0.64,0.22,1.85,1,6,,Serious adverse events Show forest plot
1.7 Disease‐specific health‐related quality of life Show forest plot,1,,"Mean Difference (IV, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,7,,Disease‐specific health‐related quality of life Show forest plot
1.7.1 6 to ≤ 12 months,1,20,"Mean Difference (IV, Random, 95% CI)","‐0.38 [‐1.56, 0.80]",Intratympanic corticosteroids versus placebo/no treatment,1,-0.38,-1.56,0.8,1,7,,6 to ≤ 12 months
1.7.2 > 12 months,1,18,"Mean Difference (IV, Random, 95% CI)","‐0.45 [‐2.03, 1.13]",Intratympanic corticosteroids versus placebo/no treatment,1,-0.45,-2.03,1.13,1,7,,> 12 months
1.8 Change in hearing: continuous data Show forest plot,1,,"Mean Difference (IV, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,8,,Change in hearing: continuous data Show forest plot
1.8.1 6 to ≤ 12 months,1,20,"Mean Difference (IV, Random, 95% CI)","‐4.95 [‐16.50, 6.60]",Intratympanic corticosteroids versus placebo/no treatment,1,-4.95,-16.5,6.6,1,8,,6 to ≤ 12 months
1.8.2 > 12 months,1,18,"Mean Difference (IV, Random, 95% CI)","‐2.84 [‐9.61, 3.93]",Intratympanic corticosteroids versus placebo/no treatment,1,-2.84,-9.61,3.93,1,8,,> 12 months
1.9 Improvement in hearing: dichotomous data Show forest plot,4,,"Risk Ratio (M‐H, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,9,,Improvement in hearing: dichotomous data Show forest plot
1.9.1 3 to < 6 months,2,184,"Risk Ratio (M‐H, Random, 95% CI)","0.45 [0.18, 1.15]",Intratympanic corticosteroids versus placebo/no treatment,1,0.45,0.18,1.15,1,9,,3 to < 6 months
1.9.2 6 to ≤ 12 months,2,76,"Risk Ratio (M‐H, Random, 95% CI)","0.73 [0.45, 1.17]",Intratympanic corticosteroids versus placebo/no treatment,1,0.73,0.45,1.17,1,9,,6 to ≤ 12 months
1.9.3 > 12 months,2,58,"Risk Ratio (M‐H, Random, 95% CI)","0.79 [0.46, 1.35]",Intratympanic corticosteroids versus placebo/no treatment,1,0.79,0.46,1.35,1,9,,> 12 months
1.10 Change in tinnitus Show forest plot,2,,"Mean Difference (IV, Random, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,10,,Change in tinnitus Show forest plot
1.10.1 3 to < 6 months,1,44,"Mean Difference (IV, Random, 95% CI)","‐9.69 [‐20.28, 0.89]",Intratympanic corticosteroids versus placebo/no treatment,1,-9.69,-20.28,0.89,1,10,,3 to < 6 months
1.10.2 6 to ≤ 12 months,1,20,"Mean Difference (IV, Random, 95% CI)","‐1.12 [‐24.75, 22.51]",Intratympanic corticosteroids versus placebo/no treatment,1,-1.12,-24.75,22.51,1,10,,6 to ≤ 12 months
1.10.3 > 12 months,1,18,"Mean Difference (IV, Random, 95% CI)","6.60 [‐7.79, 20.99]",Intratympanic corticosteroids versus placebo/no treatment,1,6.6,-7.79,20.99,1,10,,> 12 months
1.11 Other adverse effects Show forest plot,4,,"Peto Odds Ratio (Peto, Fixed, 95% CI)",Subtotals only,Intratympanic corticosteroids versus placebo/no treatment,1,,,,1,11,,Other adverse effects Show forest plot
1.11.1 Persistent tympanic membrane perforation,3,320,"Peto Odds Ratio (Peto, Fixed, 95% CI)","5.71 [1.56, 20.96]",Intratympanic corticosteroids versus placebo/no treatment,1,5.71,1.56,20.96,1,11,,Persistent tympanic membrane perforation
1.11.2 Ear pain,4,500,"Peto Odds Ratio (Peto, Fixed, 95% CI)","1.19 [0.47, 3.04]",Intratympanic corticosteroids versus placebo/no treatment,1,1.19,0.47,3.04,1,11,,Ear pain
1.11.3 Post‐injection vertigo,3,346,"Peto Odds Ratio (Peto, Fixed, 95% CI)","1.78 [0.65, 4.87]",Intratympanic corticosteroids versus placebo/no treatment,1,1.78,0.65,4.87,1,11,,Post‐injection vertigo
"1.11.4 New onset, permanent and total hearing loss in the affected ear",2,172,"Peto Odds Ratio (Peto, Fixed, 95% CI)","3.47 [0.02, 486.20]",Intratympanic corticosteroids versus placebo/no treatment,1,3.47,0.02,486.2,1,11,,"New onset, permanent and total hearing loss in the affected ear"
1.11.5 New onset of tinnitus in the affected ear,2,302,"Peto Odds Ratio (Peto, Fixed, 95% CI)","1.09 [0.30, 3.91]",Intratympanic corticosteroids versus placebo/no treatment,1,1.09,0.3,3.91,1,11,,New onset of tinnitus in the affected ear
